Synonym
PK-083; PK 083; PK083; PhiKan 083; PhiKan083; PhiKan-083;
IUPAC/Chemical Name
1-(9-Ethyl-9H-carbazol-3-yl)-N-methylmethanamine
InChi Key
LBPNOEAFWYTTEB-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H18N2/c1-3-18-15-7-5-4-6-13(15)14-10-12(11-17-2)8-9-16(14)18/h4-10,17H,3,11H2,1-2H3
SMILES Code
CNCC1=CC2=C(C=C1)N(CC)C3=C2C=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
238.33
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Haq BU, Qayoom H, Sofi S, Jan N, Shabir A, Ahmad I, Ahmad F, Almilaibary A, Mir MA. Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis. Front Pharmacol. 2024 Jan 10;14:1333447. doi: 10.3389/fphar.2023.1333447. PMID: 38269278; PMCID: PMC10806237.
2: Raghavan V, Agrahari M, Gowda DK. Virtual screening of p53 mutants reveals Y220S as an additional rescue drug target for PhiKan083 with higher binding characteristics. Comput Biol Chem. 2019 Jun;80:398-408. doi: 10.1016/j.compbiolchem.2019.05.005. Epub 2019 May 16. PMID: 31128451.
3: Paulmurugan R, Afjei R, Sekar TV, Babikir HA, Massoud TF. A protein folding molecular imaging biosensor monitors the effects of drugs that restore mutant p53 structure and its downstream function in glioblastoma cells. Oncotarget. 2018 Apr 20;9(30):21495-21511. doi: 10.18632/oncotarget.25138. PMID: 29765555; PMCID: PMC5940411.
4: Bauer MR, Jones RN, Baud MG, Wilcken R, Boeckler FM, Fersht AR, Joerger AC, Spencer J. Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs. ACS Chem Biol. 2016 Aug 19;11(8):2265-74. doi: 10.1021/acschembio.6b00315. Epub 2016 Jun 21. PMID: 27267810; PMCID: PMC4994063.
5: Rauf SM, Endou A, Takaba H, Miyamoto A. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach. Protein J. 2013 Jan;32(1):68-74. doi: 10.1007/s10930-012-9458-x. PMID: 23315175.
6: Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene. 2010 Jul 29;29(30):4245-52. doi: 10.1038/onc.2010.188. Epub 2010 May 24. PMID: 20498645.
7: Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10360-5. doi: 10.1073/pnas.0805326105. Epub 2008 Jul 23. PMID: 18650397; PMCID: PMC2492497.
; PMCID: PMC1051534.
